The Food and Drug Administration (FDA) has mandated the recall of over 3.1 million bottles of lubricating eye drops manufactured by K.C. Pharmaceuticals due to concerns that the products failed to prove adequate sterility. The recall, initiated on March 3, 2026, highlights ongoing quality control issues at the company's facility in Pomona, California.
Details of the Product Recall
K.C. Pharmaceuticals is recalling eight different types of eye drops sold under various brand names at major national retailers. The primary concern is that the products may not be sterile, posing a risk of severe eye infections.
- Affected Company: K.C. Pharmaceuticals
- Total Units Recalled: Over 3.1 million bottles
- Reason for Recall: Failure to prove product sterility, raising contamination risks.
- Products Affected: Includes Dry Eye Relief Eye Drops, Artificial Tears Sterile Lubricant Eye Drops, and several other sterile formulations.
- Retailers: The products were sold at major stores including Walgreens, CVS, Rite Aid, Kroger, and others.
Consumers who purchased eye drops since April 2025 are advised to check the FDA website using the product name, lot number, and expiration date to determine if their specific batch is included in the recall.
Health Risks and Safety Warnings
Clinical pharmacologists warn that using non-sterile eye drops can harbor bacteria and fungus, leading to serious eye infections. Symptoms requiring immediate medical attention include:
- Redness in the eyes.
- Eyelids sticking together.
- Unusual eye discharge (goo or pus).
- Vision changes, swelling, or persistent eye pain/itchiness.
Consumers are instructed to stop using any potentially recalled product immediately and return it to the store for a refund. If symptoms appear, they must seek medical attention and report the incident to the FDA.
Regulatory Oversight and History
The current recall is notable because it represents the second instance since 2023 that the FDA has identified sterility issues at K.C. Pharmaceuticals' manufacturing site. This suggests persistent quality control lapses.
- FDA Role: The FDA is responsible for overseeing the manufacturing quality of both prescription and over-the-counter drugs and protecting the public from contaminated medications.
- Previous Outbreaks: The FDA increased scrutiny following a 2023 outbreak of rare eye infections caused by drug-resistant bacteria, leading to multiple recalls and warnings for various manufacturers.
- Prior Warning: In addition to the current recall, the FDA had previously issued a warning letter to K.C. Pharmaceuticals, citing concerns that the company failed to establish and follow appropriate written procedures to prevent microbiological contamination.
Experts emphasize that the current massive recall underscores the urgent need for the manufacturer to address lingering quality control issues at its facility.
